Cell Therapeutics (CTI) is a toxic avenger. The firm creates more effective and less toxic treatments for various forms of cancer. CTI is developing a number of cancer-fighting compounds, including pixantrone, a treatment for non-Hodgkin's lymphoma and other tumorous cancers, and Opaxio (paclitaxel poliglumex) for non-small cell lung and ovarian cancers. The company's Systems Medicine subsidiary is working on a potential sarcoma-fighter called brostallicin. CTI no longer markets any commercial products and instead focuses on research and development projects.